The FDA approved semaglutide to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, according to an agency announcement about the new indication. A phase III study of patients with overweight and obesity showed that semaglutide significantly reduced the composite of cardiovascular death, heart attack, and stroke by 20%. In the 3-year study, these major adverse cardiac events occurred in 6.5% of patients on semaglutide …
Read More